The assigned single protein target in the DRUGMATRIX assay is the Alpha-1D adrenergic receptor, with prazosin as the ligand for radioligand binding. The assay is in vitro and involves binding, while the HEK293 cell type and membrane subcellular fraction are used in the testing. Does the molecule exhibit effectiveness in this assay?